Integrated Advisors Network LLC Grows Stake in Amgen Inc. $AMGN

Integrated Advisors Network LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 50.5% during the first quarter, Holdings Channel.com reports. The institutional investor owned 18,941 shares of the medical research company’s stock after buying an additional 6,356 shares during the quarter. Integrated Advisors Network LLC’s holdings in Amgen were worth $6,664,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after acquiring an additional 961,975 shares in the last quarter. State Street Corp raised its holdings in Amgen by 4.4% in the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after purchasing an additional 1,287,310 shares in the last quarter. Capital World Investors lifted its position in shares of Amgen by 22.9% in the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares during the period. Capital International Investors lifted its position in shares of Amgen by 1.5% in the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after purchasing an additional 282,219 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after purchasing an additional 1,035,779 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.85% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Truist raised its price target on Amgen to $340 from $327, signaling slightly improved expectations even though it kept a hold rating. Benzinga report on Truist target increase
• Positive Sentiment: Zacks upgraded Amgen to Buy (Rank #2), citing better earnings outlook, which could support shares in the near term. Yahoo Finance/Zacks upgrade report
• Neutral Sentiment: Cantor Fitzgerald reaffirmed its neutral rating and set a $350 target, indicating the stock may be priced a bit ahead of fundamentals. American Banking News Cantor Fitzgerald report
• Negative Sentiment: Amgen was also highlighted as trading below market strength in a recent report, reflecting pressure on the shares after a prior decline and ongoing investor caution around Tavneos and pipeline prospects. Yahoo Finance stock dips report
• Negative Sentiment: Quiver Quant noted regulatory scrutiny of Tavneos and questions about Amgen’s pipeline, especially in obesity, which has weighed on investor sentiment. Quiver Quant analysis

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Canaccord Genuity Group started coverage on Amgen in a research report on Monday, April 20th. They set a “hold” rating and a $366.00 price objective on the stock. Jefferies Financial Group initiated coverage on Amgen in a report on Tuesday, March 10th. They set a “hold” rating and a $350.00 target price on the stock. Finally, UBS Group raised their target price on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus price target of $356.00.

Amgen Stock Up 0.5%

Shares of AMGN stock traded up $1.92 during trading hours on Tuesday, hitting $368.36. 388,232 shares of the company’s stock traded hands, compared to its average volume of 2,768,147. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The stock’s fifty day simple moving average is $342.43 and its two-hundred day simple moving average is $348.09. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $391.29. The stock has a market cap of $198.80 billion, a price-to-earnings ratio of 25.67, a PEG ratio of 3.68 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the business posted $4.90 EPS. The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts expect that Amgen Inc. will post 22.39 EPS for the current year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.